Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

Armando Giuliano to receive the 2025 William L. McGuire Memorial Lecture Award

Armando E. Giuliano will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9-12 at the Henry B. Gonzalez Convention Center in San Antonio.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Tukysa improves HER2+ breast cancer, phase III trial shows

The phase III HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor Tukysa in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer has met its primary endpoint.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy

Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

Mayo Clinic administered an investigational radioactive medicine to a patient with hepatocellular carcinoma.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

In Brief

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Researchers at Moffitt Cancer Center have been awarded a $22.4 million grant from the U.S. Department of War to lead studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers that spreads to the coverings of the brain and spinal cord.

October 10, 2025

Vol.51 No.37

Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

YOU MAY BE INTERESTED IN

Armando Giuliano to receive the 2025 William L. McGuire Memorial Lecture Award

Tukysa improves HER2+ breast cancer, phase III trial shows

Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy

Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

Moffitt receives $22.4M grant to advance research and clinical trials for leptomeningeal disease

Renew today!

Subscriber content

Never miss an issue!

Login